# A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

> **NCT04547907** · PHASE3 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 688 (estimated)

## Conditions studied

- Breast Cancer,HER2-positive

## Interventions

- **DRUG:** Nab-paclitaxel+ trastuzumab+ patuzumab
- **DRUG:** Docetaxel+ carboplatin+ trastuzumab + patuzumab

## Key facts

- **NCT ID:** NCT04547907
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-18
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 688 (ESTIMATED)
- **Last updated:** 2024-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04547907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04547907, "A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04547907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*